{"nctId":"NCT01077076","briefTitle":"Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)","startDateStruct":{"date":"2008-12"},"conditions":["Intragastric Acidity"],"count":30,"armGroups":[{"label":"Zegerid OTC Capsules","type":"EXPERIMENTAL","interventionNames":["Drug: Zegerid"]},{"label":"Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prilosec OTC™ Tablets"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Zegerid","otherNames":[]},{"name":"Prilosec OTC™ Tablets","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-lactating, non-pregnant female subjects who are 18-65 years of age.\n* Physical examination findings within normal limits for age.\n\nExclusion Criteria:\n\n* History of hypersensitivity, allergy or intolerance to omeprazole, or other proton pump inhibitors\n* History of peptic ulcer disease or other acid related gastrointestinal symptoms or heartburn with a frequency of more than one/month.\n* Participation in any study of an investigational treatment in the 30 Days before Screening or participation in another study at any time during the period of this study\n* Any significant medical illness that would contraindicate participation in the study\n* Gastrointestinal disorder or surgery leading to impaired drug absorption\n* Any abnormal Screening laboratory value that is clinically significant in the investigator's opinion\n* Current use of any prescription or OTC medications that affect gastrointestinal function.\n* Currently using or having a history of frequent use of antacids, OTC or prescription (Rx) histamine-2 (H2) receptor antagonists, or OTC or Rx use of proton pump inhibitors.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment","description":"Early effectiveness of treatment is evaluated as the percent time with intragastric pH\\>4 during the first 4 hours following administration of respective treatments","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.265","spread":"27.588"},{"groupId":"OG001","value":"46.933","spread":"21.885"},{"groupId":"OG002","value":"17.215","spread":"15.432"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Upper Respiratory Tract Infection"]}}}